ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Testosterone replacement protects men with preexisting heart disease
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 36478" data-attributes="member: 3"><p><strong>1206M-07 - Clinical Effects of Testosterone Supplementation Among Hypo-Androgenic Men With Preexisting Severe Coronary Artery Disease: The Intermountain Heart Collaborative Study</strong></p><p></p><p></p><p><a href="http://www.abstractsonline.com/pp8/#!/3874/presentation/43323" target="_blank">http://www.abstractsonline.com/pp8/#!/3874/presentation/43323</a></p><p></p><p>[ATTACH]1925[/ATTACH]</p><p></p><p></p><p>Authors</p><p>Tami L. Bair, Heidi May, Viet T. Le, Donald Lappe, Jeffrey Anderson, J. Muhlestein, Intermountain Medical Center, Murray, UT, USA</p><p></p><p>Abstract</p><p></p><p>Introduction: Low serum testosterone (T) is an independent risk factor for CV and total mortality. The impact of T therapy on CV outcomes, especially among older men with pre-existing severe CAD, is unknown.</p><p></p><p>Methods: All men >50 yrs of age, with severe CAD (≥70% stenosis), a low (<212 ng/dL) baseline T level, 1 follow-up (f/u) T level and 3 yrs of clinical f/u were evaluated. T was stratified into categories: persistent low (<212), normal (212-742), and high (>742). Cox hazard regression analysis was performed to associate T categories with major adverse cardiovascular events (MACE) including death [D], non-fatal MI, and stroke.</p><p></p><p>Results: A total of 755 men (age 68.0 ± 9.6 y, diabetes: 50%, hypertension: 83%, hyperlipidemia: 81%, smokers: 33%, prior MI: 23%) were studied. Event rates at 1 and 3-y by achieved T level, and adjusted HRs, are shown in Table. Overall 3-y rates of MACE, D and MI were 24.5%, 17.6% and 8.1% respectively. Pts supplemented to normal/high T had reduced 3-y MACE (HR=0.77 [0.56-1.04]), D (HR=0.67 [0.47-0.97]) and MI (HR 0.52 [0.31, 0.87]) compared to low T subjects. Results were similar for 1-y MACE (HR=0.63 [0.40, 1.00]), D (HR=0.93 [0.51, 1.69]) and MI (HR=0.26 [0.31, 0.87]).</p><p></p><p>Conclusions: Among elderly men with severe CAD and low T, T therapy was associated with reduced MACE, D and MI over 3-y compared to no or ineffective supplementation. A marked protective effect of T supplementation on MI incidence during first yr of f/u was noted, giving further evidence of CV safety associated with T supplementation.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 36478, member: 3"] [B]1206M-07 - Clinical Effects of Testosterone Supplementation Among Hypo-Androgenic Men With Preexisting Severe Coronary Artery Disease: The Intermountain Heart Collaborative Study[/B] [URL]http://www.abstractsonline.com/pp8/#!/3874/presentation/43323[/URL] [ATTACH=CONFIG]1925[/ATTACH] Authors Tami L. Bair, Heidi May, Viet T. Le, Donald Lappe, Jeffrey Anderson, J. Muhlestein, Intermountain Medical Center, Murray, UT, USA Abstract Introduction: Low serum testosterone (T) is an independent risk factor for CV and total mortality. The impact of T therapy on CV outcomes, especially among older men with pre-existing severe CAD, is unknown. Methods: All men >50 yrs of age, with severe CAD (≥70% stenosis), a low (<212 ng/dL) baseline T level, 1 follow-up (f/u) T level and 3 yrs of clinical f/u were evaluated. T was stratified into categories: persistent low (<212), normal (212-742), and high (>742). Cox hazard regression analysis was performed to associate T categories with major adverse cardiovascular events (MACE) including death [D], non-fatal MI, and stroke. Results: A total of 755 men (age 68.0 ± 9.6 y, diabetes: 50%, hypertension: 83%, hyperlipidemia: 81%, smokers: 33%, prior MI: 23%) were studied. Event rates at 1 and 3-y by achieved T level, and adjusted HRs, are shown in Table. Overall 3-y rates of MACE, D and MI were 24.5%, 17.6% and 8.1% respectively. Pts supplemented to normal/high T had reduced 3-y MACE (HR=0.77 [0.56-1.04]), D (HR=0.67 [0.47-0.97]) and MI (HR 0.52 [0.31, 0.87]) compared to low T subjects. Results were similar for 1-y MACE (HR=0.63 [0.40, 1.00]), D (HR=0.93 [0.51, 1.69]) and MI (HR=0.26 [0.31, 0.87]). Conclusions: Among elderly men with severe CAD and low T, T therapy was associated with reduced MACE, D and MI over 3-y compared to no or ineffective supplementation. A marked protective effect of T supplementation on MI incidence during first yr of f/u was noted, giving further evidence of CV safety associated with T supplementation. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Testosterone replacement protects men with preexisting heart disease
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top